Catherine Tuleu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1621363/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms. Expert Opinion on Drug Delivery, 2015, 12, 1727-1740.	5.0	183
2	Playing hide and seek with poorly tasting paediatric medicines: Do not forget the excipients. Advanced Drug Delivery Reviews, 2014, 73, 14-33.	13.7	179
3	Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations. Drugs, 2014, 74, 1871-1889.	10.9	170
4	Paediatric formulations—Getting to the heart of the problem. International Journal of Pharmaceutics, 2005, 300, 56-66.	5.2	163
5	Minitablets: New Modality to Deliver Medicines to Preschool-Aged Children. Pediatrics, 2009, 123, e235-e238.	2.1	154
6	Challenges of developing palatable oral paediatric formulations. International Journal of Pharmaceutics, 2009, 365, 1-3.	5.2	111
7	Medicines for Children: A Matter of Taste. Journal of Pediatrics, 2008, 153, 599-604.e2.	1.8	89
8	Rectal route in the 21st Century to treat children. Advanced Drug Delivery Reviews, 2014, 73, 34-49.	13.7	87
9	I Spy with My Little Eye: A Paediatric Visual Preferences Survey of 3D Printed Tablets. Pharmaceutics, 2020, 12, 1100.	4.5	84
10	Ink-jet printing versus solvent casting to prepare oral films: Effect on mechanical properties and physical stability. International Journal of Pharmaceutics, 2015, 494, 611-618.	5.2	74
11	Comparative Bioavailability Study in Dogs of a Selfâ€Emulsifying Formulation of Progesterone Presented in a Pellet and Liquid form Compared with an Aqueous Suspension of Progesterone. Journal of Pharmaceutical Sciences, 2004, 93, 1495-1502.	3.3	68
12	Specific aspects of gastro-intestinal transit in children for drug delivery design. International Journal of Pharmaceutics, 2010, 395, 37-43.	5.2	66
13	The STEP (Safety and Toxicity of Excipients for Paediatrics) database: Part 2 – The pilot version. International Journal of Pharmaceutics, 2013, 457, 310-322.	5.2	66
14	Age-appropriate and acceptable paediatric dosage forms: Insights into end-user perceptions, preferences and practices from the Children's Acceptability of Oral Formulations (CALF) Study. International Journal of Pharmaceutics, 2016, 514, 296-307.	5.2	60
15	The STEP (Safety and Toxicity of Excipients for Paediatrics) database. Part 1—A need assessment study. International Journal of Pharmaceutics, 2012, 435, 101-111.	5.2	58
16	Effect of formulation variables on oral grittiness and preferences of multiparticulate formulations in adult volunteers. European Journal of Pharmaceutical Sciences, 2016, 92, 156-162.	4.0	57
17	Colonic delivery of 4-aminosalicylic acid using amylose-ethylcellulose-coated hydroxypropylmethylcellulose capsules. Alimentary Pharmacology and Therapeutics, 2002, 16, 1771-1779.	3.7	55
18	A scintigraphic investigation of the disintegration behaviour of capsules in fasting subjects: A comparison of hypromellose capsules containing carrageenan as a gelling agent and standard gelatin capsules. European Journal of Pharmaceutical Sciences, 2007, 30, 251-255.	4.0	53

#	Article	IF	CITATIONS
19	Acceptability of orodispersible films for delivery of medicines to infants and preschool children. Drug Delivery, 2017, 24, 1243-1248.	5.7	53
20	Preparation of medicines for children – A hierarchy of classification. International Journal of Pharmaceutics, 2012, 435, 124-130.	5.2	48
21	Educational Paper: Formulation-related issues in pediatric clinical pharmacology. European Journal of Pediatrics, 2013, 172, 717-720.	2.7	43
22	Non-human tools for the evaluation of bitter taste in the design and development of medicines: a systematic review. Drug Discovery Today, 2016, 21, 1170-1180.	6.4	43
23	Co-Processed Excipients for Dispersible Tablets–Part 1: Manufacturability. AAPS PharmSciTech, 2018, 19, 2598-2609.	3.3	41
24	Direct Powder Extrusion 3D Printing of Praziquantel to Overcome Neglected Disease Formulation Challenges in Paediatric Populations. Pharmaceutics, 2021, 13, 1114.	4.5	40
25	Formulation factors affecting acceptability of oral medicines in children. International Journal of Pharmaceutics, 2015, 492, 341-343.	5.2	39
26	Methodologies for assessing the acceptability of oral formulations among children and older adults: a systematic review. Drug Discovery Today, 2018, 23, 830-847.	6.4	38
27	Patient centric formulations for paediatrics and geriatrics: Similarities and differences. International Journal of Pharmaceutics, 2016, 512, 355-359.	5.2	35
28	Making Medicines Baby Size: The Challenges in Bridging the Formulation Gap in Neonatal Medicine. International Journal of Molecular Sciences, 2019, 20, 2688.	4.1	33
29	European Paediatric Formulation Initiative (EuPFI)—Formulating Ideas for Better Medicines for Children. AAPS PharmSciTech, 2017, 18, 257-262.	3.3	30
30	Solid state characterisation and taste masking efficiency evaluation of polymer based extrudates of isoniazid for paediatric administration. International Journal of Pharmaceutics, 2018, 536, 536-546.	5.2	30
31	Medicines for children: flexible solid oral formulations. Bulletin of the World Health Organization, 2017, 95, 238-240.	3.3	29
32	Public engagement workshop: How to improve medicines for older people?. International Journal of Pharmaceutics, 2014, 459, 65-69.	5.2	27
33	Development of a model for robust and exploratory analysis of the rodent brief-access taste aversion data. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 91, 47-51.	4.3	26
34	Children's Preferences for Oral Dosage Forms and Their Involvement in Formulation Research via EPTRI (European Paediatric Translational Research Infrastructure). Pharmaceutics, 2021, 13, 730.	4.5	25
35	Comparative in vitro and in vivo taste assessment of liquid praziquantel formulations. International Journal of Pharmaceutics, 2017, 529, 310-318.	5.2	24
36	Demonstrating Evidence of Acceptability: The "Catch-22―of Pediatric Formulation Development. Clinical Pharmacology and Therapeutics, 2013, 94, 582-584.	4.7	23

#	Article	IF	CITATIONS
37	Rats can predict aversiveness of Active Pharmaceutical Ingredients. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 133, 77-84.	4.3	23
38	Co-Processed Excipients for Dispersible Tablets—Part 2: Patient Acceptability. AAPS PharmSciTech, 2018, 19, 2646-2657.	3.3	22
39	Electrospinning Optimization of Eudragit E PO with and without Chlorpheniramine Maleate Using a Design of Experiment Approach. Molecular Pharmaceutics, 2019, 16, 2557-2568.	4.6	22
40	Acceptability of placebo multiparticulate formulations in children and adults. Scientific Reports, 2018, 8, 9210.	3.3	21
41	Bitter-blockers as a taste masking strategy: A systematic review towards their utility in pharmaceuticals. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 158, 35-51.	4.3	20
42	Can a Flavored Spray (Pill Glide) Help Children Swallow Their Medicines? A Pilot Study. Pediatrics, 2016, 138, e20160680-e20160680.	2.1	18
43	The Milky Way: paediatric milk-based dispersible tablets prepared by direct compression – a proof-of-concept study. Journal of Pharmacy and Pharmacology, 2017, 69, 417-431.	2.4	18
44	Taste evaluation of a novel midazolam tablet for pediatric patients: In vitro drug dissolution, in vivo animal taste aversion and clinical taste perception profiles. International Journal of Pharmaceutics, 2018, 535, 194-200.	5.2	18
45	The effect of administration media on palatability and ease of swallowing of multiparticulate formulations. International Journal of Pharmaceutics, 2018, 551, 67-75.	5.2	18
46	The STEP database through the end-users eyes—USABILITY STUDY. International Journal of Pharmaceutics, 2015, 492, 316-331.	5.2	17
47	A new reconstitutable oral paediatric hydrocortisone solution containing hydroxypropyl-β-cyclodextrin. Drug Development and Industrial Pharmacy, 2013, 39, 1028-1036.	2.0	16
48	Accuracy of enteral syringes with commonly prescribed paediatric liquid medicines. Archives of Disease in Childhood, 2017, 102, 655-659.	1.9	16
49	Palliative medicines for children – a new frontier in paediatric research. Journal of Pharmacy and Pharmacology, 2017, 69, 377-383.	2.4	15
50	In vitro and sensory tests to design easy-to-swallow multi-particulate formulations. European Journal of Pharmaceutical Sciences, 2019, 132, 157-162.	4.0	15
51	Multi-Methodological Quantitative Taste Assessment of Anti-Tuberculosis Drugs to Support the Development of Palatable Paediatric Dosage Forms. Pharmaceutics, 2020, 12, 369.	4.5	15
52	Quality and stability of extemporaneous pyridoxal phosphate preparations used in the treatment of paediatric epilepsy. Journal of Pharmacy and Pharmacology, 2017, 69, 480-488.	2.4	14
53	Short term stability of pH-adjusted lidocaine-adrenaline epidural solution used for emergency caesarean section. International Journal of Obstetric Anesthesia, 2008, 17, 118-122.	0.4	12
54	Inappropriate oral formulations and information in paediatric trials. Archives of Disease in Childhood, 2010, 95, 754-756.	1.9	12

#	Article	IF	CITATIONS
55	Characterising the disintegration properties of tablets in opaque media using texture analysis. International Journal of Pharmaceutics, 2015, 486, 136-143.	5.2	12
56	Sex Differences in Medicine Acceptability: A New Factor to Be Considered in Medicine Formulation. Pharmaceutics, 2019, 11, 368.	4.5	12
57	In Vitro Dissolution Model Can Predict the in Vivo Taste Masking Performance of Coated Multiparticulates. Molecular Pharmaceutics, 2019, 16, 2095-2105.	4.6	12
58	Path towards efficient paediatric formulation development based on partnering with clinical pharmacologists and clinicians, a conect4children expert group white paper. British Journal of Clinical Pharmacology, 2022, 88, 5034-5051.	2.4	12
59	â€~Poppy seeds' in stomach aspirates: is oral omeprazole extemporaneous dispersion bioavailable?. European Journal of Pediatrics, 2008, 167, 823-825.	2.7	11
60	â€~Formulating better medicines for children' – Still paving the road. International Journal of Pharmaceutics, 2012, 435, 99-100.	5.2	11
61	Acceptability of generic versus innovator oral medicines: not only a matter of taste. Drug Discovery Today, 2021, 26, 329-343.	6.4	11
62	Utilising Co-Axial Electrospinning as a Taste-Masking Technology for Paediatric Drug Delivery. Pharmaceutics, 2021, 13, 1665.	4.5	11
63	Modeling the Physiological Factors That Affect Drug Delivery from a Nipple Shield Delivery System to Breastfeeding Infants. Journal of Pharmaceutical Sciences, 2013, 102, 3773-3783.	3.3	10
64	A mini-review of non-parenteral clonidine preparations for paediatric sedation. Journal of Pharmacy and Pharmacology, 2017, 69, 398-405.	2.4	10
65	How Do Orodispersible Tablets Behave in an In Vitro Oral Cavity Model: A Pilot Study. Pharmaceutics, 2020, 12, 651.	4.5	9
66	Characterisation of zinc delivery from a nipple shield delivery system using a breastfeeding simulation apparatus. PLoS ONE, 2017, 12, e0171624.	2.5	8
67	Human mouthfeel panel investigating the acceptability of electrospun and solvent cast orodispersible films. International Journal of Pharmaceutics, 2020, 585, 119532.	5.2	8
68	From paediatric formulations development to access: Advances made and remaining challenges. British Journal of Clinical Pharmacology, 2022, 88, 4349-4383.	2.4	8
69	In Vivo Investigation of (2-Hydroxypropyl)-β-cyclodextrin-Based Formulation of Spironolactone in Aqueous Solution for Paediatric Use. Pharmaceutics, 2022, 14, 780.	4.5	8
70	Formulating better medicines for children—reflections. International Journal of Pharmaceutics, 2015, 492, 301-303.	5.2	7
71	Modernising Orodispersible Film Characterisation to Improve Palatability and Acceptability Using a Toolbox of Techniques. Pharmaceutics, 2022, 14, 732.	4.5	7
72	Formulating better medicines for children—Still too far to walk. International Journal of Pharmaceutics, 2016, 511, 1124-1126.	5.2	6

#	Article	IF	CITATIONS
73	Characterisation of rectal amoxicillin (RAMOX) for the treatment of pneumonia in children. Drug Delivery and Translational Research, 2021, 11, 944-955.	5.8	6
74	New generalized poisson mixture model for bimodal count data with drug effect: An application to rodent briefâ€access taste aversion experiments. CPT: Pharmacometrics and Systems Pharmacology, 2016, 5, 427-436.	2.5	5
75	Access to age-appropriate essential medicines: a retrospective survey of compounding of medicines for children in hospitals in Nigeria and implications for policy development. Health Policy and Planning, 2016, 32, czw115.	2.7	5
76	Proposed Tool to Compare and Assess the Applicability of Taste Assessment Techniques for Pharmaceuticals. Journal of Pharmaceutical Sciences, 2022, 111, 1219-1223.	3.3	5
77	â€~Formulating better medicines for children' – Setting the pace for the future. International Journal of Pharmaceutics, 2013, 457, 308-309.	5.2	4
78	ACCURACY OF ENTERAL SYRINGES FOR LIQUID MEDICINES PRESCRIBED IN CHILDREN. Archives of Disease in Childhood, 2014, 99, e3-e3.	1.9	4
79	Paediatric Solid Formulations. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 153-170.	0.6	4
80	Opportunities for enteral drug delivery for neonates, infants, and toddlers: a critical exploration. Expert Opinion on Drug Delivery, 2022, 19, 475-519.	5.0	4
81	â€~Formulating better medicines for children' – The leap forward. International Journal of Pharmaceutics, 2014, 469, 225-227.	5.2	3
82	Mimicking the Impact of Infant Tongue Peristalsis on Behavior of Solid Oral Dosage Forms Administered During Breastfeeding. Journal of Pharmaceutical Sciences, 2017, 106, 193-199.	3.3	3
83	A survey of caregivers of Nigerian children less than 6 years of age to determine the experience and perception of acceptability of oral solid dosage forms. International Journal of Pharmaceutics, 2018, 536, 582-589.	5.2	3
84	The rectal route of medicine administration for children: Let's get to the bottom of it!. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 157, 25-27.	4.3	3
85	Evaluating the Taste Masking Ability of Two Novel Dispersible Tablet Platforms Containing Zinc Sulfate and Paracetamol Reconstituted in a Breast Milk Substitute. Pharmaceutics, 2022, 14, 420.	4.5	3
86	Quality and clinical supply considerations of Paediatric Investigation Plans for IV preparations—A case study with the FP7 CloSed project. International Journal of Pharmaceutics, 2016, 511, 1158-1162.	5.2	2
87	Using the Slug Mucosal Irritation Assay to Investigate the Tolerability of Tablet Excipients on Human Skin in the Context of the Use of a Nipple Shield Delivery System. Pharmaceutical Research, 2017, 34, 687-695.	3.5	2
88	Better medicines for children: are we there yet?. Journal of Pharmacy and Pharmacology, 2017, 69, 349-349.	2.4	1
89	â€~Big Data' informed drug development: a case for acceptability. Drug Discovery Today, 2021, 26, 865-869.	6.4	1
90	Better medicines for children: are we there yet?. Journal of Pharmacy and Pharmacology, 2017, 69, 497-497.	2.4	0

#	Article	IF	CITATIONS
91	Rectal Drug Delivery to Paediatric Population. Hrvatski CÌŒasopis Zdravstvenih Znanosti, 2021, 1, 76-80.	0.0	Ο